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Abstract
Objective—Hypoglycemia, the limiting factor in the glycemic management of diabetes, is the result
of the interplay of therapeutic insulin excess and compromised glycemic defenses. The key feature
of the latter is an attenuated sympathoadrenal response to hypoglycemia that typically follows an
episode of recent antecedent iatrogenic hypoglycemia, a phenomenon termed hypoglycemia-
associated autonomic failure (HAAF) in diabetes. We investigated the role of cerebral mechanisms
in HAAF by measuring regional brain activation during recurrent hypoglycemia with attenuated
counterregulatory responses and comparing it to initial hypoglycemia in healthy individuals.
Research Design and Methods—We used [15O]water and positron emission tomography to
measure regional cerebral blood flow (CBF) as a marker of brain synaptic activity during
hyperinsulinemic hypoglycemic clamps (55 mg/dL [3.0 mmol/L]) in the naïve condition (Day 1) and
after ∼24 hours of interval interprandial hypoglycemia (Day 2) in nine healthy adults.
Results—Interval hypoglycemia produced attenuated sympathoadrenal, symptomatic and other
counterregulatory responses to hypoglycemia on Day 2, a model of HAAF. Synaptic activity in the
dorsal midline thalamus during hypoglycemia was significantly greater on Day 2 than Day 1
(P=0.004).
Conclusion—Greater synaptic activity associated with attenuated counterregulatory responses
indicates that the dorsal midline thalamus plays an active inhibitory role in reducing sympathoadrenal
and symptomatic responses to hypoglycemia when previous hypoglycemia has occurred, the key
feature of HAAF in diabetes.
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Iatrogenic hypoglycemia is the limiting factor in the glycemic management of diabetes (1). It
causes recurrent morbidity in most people with type 1 diabetes and many with advanced type
2 diabetes, and is sometimes fatal. Furthermore, the barrier of hypoglycemia precludes
maintenance of euglycemia over a lifetime of diabetes and thus full realization of the long-
term benefits of glycemic control. Finally, episodes of hypoglycemia further impair defenses
against falling plasma glucose concentrations and therefore cause a vicious cycle of recurrent
hypoglycemia.
Hypoglycemia in diabetes is the result of the interplay of therapeutic insulin excess and
compromised physiological and behavioral defenses against falling plasma glucose
concentrations (1-3). The key feature of the latter is an attenuated sympathoadrenal response
to hypoglycemia that causes the clinical syndromes of hypoglycemia unawareness (which is
largely the result of a reduced sympathetic neural response [4]) and defective glucose
counterregulation (which is the result of a reduced adrenomedullary epinephrine response in
the setting of absent decrements in insulin and absent increments in glucagon in insulin
deficient diabetes - type 1 diabetes and advanced [i.e., absolutely insulin deficient] type 2
diabetes). These syndromes increase the risk of severe iatrogenic hypoglycemia ∼6-fold (5)
and 25-fold or more (6,7) respectively in type 1 diabetes. Because of the key pathophysiological
role of the attenuated sympathoadrenal response, which is typically caused by recent antecedent
hypoglycemia (1-3) but also follows exercise (8) and occurs during sleep (9), this phenomenon
has been termed hypoglycemia-associated autonomic failure (HAAF) in diabetes (1-3). A
similar phenomenon of reduced sympathoadrenal responses to hypoglycemia after a period of
antecedent hypoglycemia can be produced in normal subjects and serves as a human model to
study the mechanisms of HAAF (10).
The mechanisms of HAAF are not known (1). While the fundamental alteration could be in
the afferent or efferent components of the sympathoadrenal system, it is often assumed to reside
within the CNS. Potential mechanisms, most focused on the hypothalamus, have been reviewed
(11,12).
Measurements of the increase from baseline in regional cerebral blood flow with [15O]water
and positron emission tomography (PET) can be used to identify regions of increased brain
synaptic activity and determine which brain regions are involved with different physiological
activities (13). In normal human subjects, we have reported that hypoglycemia causes increased
synaptic activity in a discrete network of interconnected brain regions including medial
prefrontal cortex, orbito-prefrontal cortex, thalamus and periaqueductal grey. These structures
are part of a system that mediates autonomic responses to various different stimuli (14). We
have now investigated the role of cerebral mechanisms in HAAF by measuring regional brain
synaptic activity during recurrent hypoglycemia with attenuated counterregulatory responses
and comparing it to initial hypoglycemia.
Design and Methods
Subjects
Nine healthy young adults (4 women/5 men, mean [±SD] age 25±3 years, body mass index
23.7±2.8 kg/m2) gave their written informed consent to participate in this study which was
approved by the Washington University Human Research Protection Office and conducted at
the Washington University General Clinical Research Center (GCRC) and Neurology-
Neurosurgery ICU PET Research Facility. All had negative medical histories and normal
physical examinations, normal fasting plasma glucose concentrations, serum creatinine
concentrations and hematocrits, and normal electrocardiograms. None had a personal or first
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degree relative history of diabetes, psychiatric or neurological conditions. These were different
subjects than in our previous study (14).
Experimental Design
Subjects were admitted to the GCRC and studied over two consecutive days after overnight
fasts. On the morning of Day 1 two intravenous catheters were inserted into arm veins (for
infusions) and one intravenous catheter was inserted into a dorsal hand vein with that hand
kept in an ∼55°C plexiglas box (for arterialized venous sampling). Hyperinsulinemic (regular
human insulin, Novo Nordisk, Bagsværd, Denmark in a dose of 2.0 mU·kg-1·min.-1)
euglycemic (90 mg/dL [5.0 mmol/L] × ∼2hours) and then hypoglycemic (55 mg/dL [3.0 mmol/
L]) × ∼2 hours) clamps - variable infusions of 20% dextrose based on plasma glucose
determinations (YSI Glucose Analyzer 2, Yellow Springs Instruments, Yellow Springs, OH)
every five minutes - were performed on the mornings of Day 1 and Day 2. [15O]water positron
emission tomography (PET) measurements of regional cerebral blood flow (see below) were
performed four times at 15 minute intervals during the second hour of euglycemia and four
times at 15 minute intervals during the second hour of hypoglycemia on both days. Arterialized
venous samples for the analytes described below were drawn, blood pressures and heart rates
were recorded and symptom scores were determined every 15 minutes, and the
electrocardiogram was monitored, throughout. To quantitate symptoms subjects were asked to
score (from 0, none, to 6, severe) six neurogenic (autonomic) symptoms - heart pounding,
shaky/tremulousness and nervous/anxious (adrenergic) and sweaty, hungry and tingling
(cholinergic) - and six neuroglycopenic symptoms - difficulty thinking/confused, tired/drowsy,
weak, warm, faint and dizzy (15). After completion of the glucose clamps/PET studies on Day
1 interprandial plasma glucose concentrations were held at ∼55 mg/dL (3.0 mmol/L) with
variable intravenous insulin infusions until they were increased to 90 mg/dl [5.0 mmol/L] at
the start of the clamps on the morning of Day 2.
Neuroendocrine and Metabolic Analytical Methods
Plasma glucose concentrations were measured with a glucose oxidase method (YSI Glucose
Analyzer 2, Yellow Springs Instruments, Yellow springs, OH). Plasma epinephrine and
norepinephrine concentrations were measured with a single isotope derivative
(radioenzymatic) method (16) and plasma insulin (17), C-peptide (17), glucagon (18),
pancreatic polypeptide (19), cortisol (20) and growth hormone (21) were measured with
radioimmunoassays. Serum nonesterified fatty acid (22) and blood lactate (23) concentrations
were measured with enzymatic techniques.
Relevant systemic variables during euglycemia on Days 1 and 2 and during hypoglycemia on
Days 1 and 2 were contrasted with a t-test for paired data. P values less than 0.05 were
considered to indicate significant differences.
Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging
PET studies were performed with a Siemens/CTI (Knoxville, TN) ECAT EXACT HR 47
tomograph located in the Neurology-Neurosurgery Intensive Care Unit PET Research Facility
(24). Subjects were positioned in the tomograph such that the entire brainstem was included
within the 15 cm axial field of view. As a result, the vertex of the brain was not included within
the study area. An individual transmission scan was obtained for each subject and used for
subsequent attenuation correction of emission scan data. Regional cerebral blood flow (rCBF)
was measured with a 40 sec emission scan after bolus intravenous injection of 50 mCi of
[15O]water (1 Ci = 37 GBq) using an adaptation of the Kety autoradiographic method
(25-27). PET scans were acquired in the two-dimensional mode (interslice septa extended).
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PET images were reconstructed using filtered back projection and measured attenuation. Each
subject’s attenuation correction was co-registered to each emission scan prior to the final
reconstruction in order to eliminate spatial variation in attenuation from each individual’s
difference images. Reconstructed images were smoothed with a 3-D Gaussian filter to a
resolution of 10 mm full-width at half-maximum. Next, each subject’s images were co-
registered to each other (28), and the mean of all of that subject’s images was co-registered to
a standard mean blood flow image in Talairach atlas space (29). All individual images were
normalized using mean whole-brain counts. The 4 euglycemic and the 4 hypoglycemic images
for each subject were combined into single state images for each day to increase statistical
precision (30). Images of regional CBF differences between euglycemia and hypoglycemia on
Day 1 and on Day 2 were created by image subtraction. For the group data these two subtraction
images, each representing the regions of brain activation during acute hypoglycemia on each
day, were examined for differences with SPM99 (31) using a fixed effects model with multiple
comparisons correction for the entire volume. T values were computed at each voxel, and
clusters of at least 90 voxels (1 resel) with uncorrected P<0.005 were identified. The statistical
significance of these clusters was computed and corrected for the number of possible clusters
of their size and magnitude within the brain volume (32,33). This analysis determines areas
where differences in CBF occur without any pre-specification of regions of interest. Location
of regions of significant change is expressed in x, y, z, stereotactic coordinates in mm with
positive values representing right, anterior, and superior respectively (29).
Each subject also underwent structural magnetic resonance (MR) imaging of the brain with a
1.5 T system (Magnetom Sonata, Siemens, Erlangen, Germany). A three dimensional
magnetization-prepared rapid gradient echo (MPRAGE) sequence (1900/1100/3.9 repetition
time/ inversion time/echo time (ms); flip angle = 15°) was acquired in a sagittally oriented
plane (160 mm thick, 128 partitions, 256 mm field of view) and reconstructed into a 256 × 256
matrix (1 × 1 × 1.25 mm pixels).
Results
Plasma Insulin C-peptide and Glucose and Glucose Infusion Rates (Table 1)
Plasma insulin concentrations were raised substantially and plasma glucose targets were met
during the euglycemic and hypoglycemic clamps on Days 1 and 2 (Table 1). Glucose infusion
rates required to maintain both the euglycemic and the hypoglycemic clamps were lower,
following interval hypoglycemia, on Day 2 (Table 1). Plasma C-peptide concentrations were
suppressed during hypoglycemic clamps on both Days (Table 1).
Symptomatic Neuroendocrine and Metabolic Responses to Hypoglycemia (Table 1)
Symptom scores and plasma epinephrine, glucagon, pancreatic polypeptide and cortisol
concentrations during hypoglycemia were reduced, following interval hypoglycemia, on Day
2, as were the required glucose infusion rates and blood lactate concentrations. Serum
nonesterified fatty acid concentrations were suppressed under these hyperinsulinemic
conditions.
Regional Cerebral Blood Flow (Figure 1)
The regional CBF patterns during euglycemia on Day 2, following interval hypoglycemia,
were not different from those on Day 1 (data not shown). The only brain region that showed a
significantly greater increase in CBF during hypoglycemia on Day 2 compared to Day 1 was
the thalamus (corrected P=0.004). The size of the significant Day 2 cluster was 207 voxels.
The region of CBF change was centered in the left pulvinar (x = -14, y = -30, z = 7) and included
the dorsal medial and paraventricular nuclei of the thalamus bilaterally (Figure 1) (34).
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These data again document that recent antecedent hypoglycemia - here ∼12-14 hours of interval
interprandial hypoglycemia - produces in healthy humans (10) a model of hypoglycemia-
associated autonomic failure (HAAF) in diabetes (1-3) including the key feature of HAAF, an
attenuated sympathoadrenal response to subsequent hypoglycemia. Compared with the
responses on Day 1, the adrenomedullary plasma epinephrine response and the largely
sympathetic neural symptomatic response (4) (among other responses) to hypoglycemia were
reduced on Day 2, following interval hypoglycemia. Thus, the phenomenon we sought to
explain mechanistically, HAAF in diabetes, was produced experimentally in these nondiabetic
individuals.
We have used the technique of measuring changes in regional CBF with positron emission
tomography (PET) to identify regions of increased synaptic activity during hypoglycemia
(13). This approach requires that the physiological coupling between increases in neuronal
activity and increases in regional CBF remains intact under these conditions. We have
previously shown that this coupling is preserved with arterial hypoglycemia to 2.3 mmol/L (41
mg/dL) (35). We measured regional CBF on two consecutive days with interval hypoglycemia.
Repeat PET CBF studies show no significant differences within the same scanning session
(36). Furthermore, [18F]deoxyglucose PET studies of metabolism performed 1 to 18 days apart
show no changes in thalamic uptake normalized for whole brain counts as was done here
(37,38). In the present study the regional CBF patterns during euglycemia on Day 2 were not
different from these on Day 1. Therefore, the observed difference in the regional CBF response
to hypoglycemia is unlikely to be an order effect. Areas of increased CBF primarily reflect the
increased metabolic activity of synaptic fields, not the spike firing rate of neuronal cell bodies
(39,40). Thus, the definitive finding of this study was a significantly greater increase in synaptic
activity in the dorsal midline thalamus during recurrent hypoglycemia with attenuated
counterregulatory responses as compared to initial hypoglycemia with robust
counterregulatory responses. The center of this region is virtually identical (x = -14, y = -30,
z = 7) to the region of increase during initial hypoglycemia (x = -11, y = -23, z = 6) that we
identified in our previous study as part of a brain network that mediates autonomic responses
to various stimuli and includes the dorsal medial and paraventricular nuclei of the thalamus
bilaterally (14). The finding of greater synaptic activity associated with attenuated
counterregulatory responses indicates that the dorsal midline thalamus plays an active
inhibitory role in reducing the sympathoadrenal and symptomatic responses to hypoglycemia
when previous hypoglycemia has occurred, the key feature of HAAF in diabetes.
Sympathoadrenal (and glucagon) responses to systemic hypoglycemia are directly stimulated
by reduced local hypothalamic glucose concentrations (41-44). These responses are reduced
by both lesions of the ventromedial hypothalamus and by maintenance of high extracellular
hypothalamic glucose concentrations (41,42). They can be mimicked by selective
hypothalamic cellular glucopenia with systemic euglycemia (43). In chronically systemically
hypoglycemic rats, the epinephrine responses to selective hypothalamic cellular glucopenia
with systemic euglycemia are attenuated. This observation is consistent with inhibition of the
normal hypothalamic response to hypoglycemia in response to antecedent hypoglycemia
(44).
Given the role of the hypothalamus as the central integrator of the sympathoadrenal response
to hypoglycemia (41-44), the novel finding reported here extends the regulation of the
sympathoadrenal response to include the dorsal midline thalamus. To our knowledge there is
no precedent for a role of the dorsal midline thalamus in the regulation of the sympathoadrenal
response to hypoglycemia. However, that region of the thalamus includes the paraventricular
nucleus of the thalamus (PVNT) and there is evidence that activation of the PVNT mediates
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habituation of the pituitary-adrenocortical response to recurrent restraint stress in rats (45).
Therefore, given the present finding, it is reasonable to suggest that increased PVNT activation
might mediate habituation of the sympathoadrenal response to recurrent hypoglycemia in
humans, the key feature of HAAF in diabetes. Indeed, given the neuroanatomical connections
of the dorsal midline thalamus and their physiological functions (46-54) we could postulate a
cerebral network - including the medial prefrontal cortex, orbito-medial prefrontal cortex,
hippocampus, amygdala, periaqueductal grey and thalamus - regulating the hypothalamic
response to recurrent hypoglycemia. Clearly, however, the documentation and definition of
such a cerebral network awaits further study.
This construct of the pathophysiology of HAAF is consistent with the findings of Cranston et
al. (55). Using [18F]deoxyglucose and positron emission tomography, they found that
deoxyglucose uptake decreased in the subthalamic region of the brain during hypoglycemia in
patients with T1DM and hypoglycemia unawareness whereas it was little changed in patients
with hypoglycemia awareness. Since that subthalamic region is centered in the hypothalamus,
it may well have been inhibited by the increased thalamic activity documented in the present
study.
To unequivocally establish the causal nature of thalamic activation in HAAF will require
demonstration that direct inhibition or ablation of dorsal medial thalamic nuclei prevents
attenuation of counterregulatory responses to recurrent hypoglycemia. Surgically implanted
electrodes in the thalamus, currently used to treat intractable tremor, provide a means to further
investigate this mechanism and may in the future offer a novel approach to treatment of HAAF
(56).
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Regional cerebral blood flow changes during hypoglycemia illustrating greater synaptic
activity in bilateral dorsal midline thalamus on Day 2, following ∼24 hours of interval
interprandial hypoglycemia, compared with Day 1. These are combined subtraction images
from all PET scans from all nine subjects superimposed on the combined MR image. The color
scales show changes relative to mean global blood flow. A maximum of 12% is used for all
scales. However, the maximum change for Day 2 was 18% compared with 10% on Day 1. A.
Mid-sagittal slices. B. Coronal slices at the level of the paraventricular nuclei (y = -19) with
the left of the brain on the left (33).
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Table 1
Mean (±SE) neuroendocrine, metabolic and symptom values during the second hour (at the times of the PET scans)
of clamped euglycemia and hypoglycemia on Day 1 and, after interval interprandial hypoglycemia (∼55 mg/dL [3.0
mmol/L]), on Day 2. The statistical contrasts shown are between Day 1 and Day 2
---Euglycemia--- --Hypoglycemia--
Day 1 Day 2 Day 1 Day 2
Insulin (μU/mL) 103±5 93±4 97±6 87±6
Glucose (mg/dL) 90±1 91±1 55±1 54±1
Glucose Infusion Rate (mg·kg-1·min.-1) 8.7±0.9 4.4±0.6a 6.5±0.6 5.2±0.8e
C-peptide (ng/mL) 1.0±0.1 0.7±0.1c 0.4±0.0 0.4±0.0
Symptom Score 4.8±1.2 3.5±0.4 10.1±1.6 5.8±0.8e
Epinephrine(pg/mL) 44±18 45±12 365±96 149±27b
Norepinephrine (pg/mL) 207±26 239±12 300±32 266±16
Glucagon (pg/mL) 77±7 67±6 107±9 80±7a
Pancreatic Polypeptide (pg/mL) 67±12 65±9 553±71 100±29e
Cortisol (μg/dL) 11.8±1.4 12.0±1.8 18.0±2.8 13.1±1.5d
Growth Hormone (ng/mL) 0.2±0.1 1.1±0.3 17.5±1.0 15.9±2.7
Lactate (mmol/L) 1.21±0.13 0.80±0.11b 31±0.13 0.79±0.09c
Nonesterified Fatty Acids (μmol/L) 161±25 237±79 167±28 245±62
To convert insulin to pmol/L multiply by 6.0, glucose to mmol/L multiply by 0.05551, glucose infusion rate to μmol·kg-1·min.-1 multiply by 5.551, c-
peptide to nmol/L multiply by 0.331, epinephrine to pmol/L multiply by 5.458, norepinephrine to nmol/L multiply by 0.005911, glucagon to pmol/L
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